Titan Pharma up after itching therapy implant shows promise in animal study

Titan Pharmaceuticals

23/06/2021 15:13

** Shares of drugmaker  TTNP.O  up 5.5% at $2.58
    ** Co reports positive data from animal study testing
implants of its experimental therapy, TP-2021, in treating
moderate to severe chronic pruritus (https://refini.tv/3xIBojC)
    ** Chronic pruritus is characterized by itching of the skin
lasting longer than six weeks
    ** TP-2021 implants provided sustained itch suppression for
a period of 14 days post-implantation in mice - TTNP
    ** Titan bought TP-2021, formerly known as JT-09, from JT
Pharma in October  urn:newsml:reuters.com:*:nL4N2HJ3WM

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))